Clinical Trial News and Research

RSS

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Matt G. Kushner, Ph.D., professor of Psychiatry, University of Minnesota (Minneapolis) has earned the latest Dan Anderson Research Award for his study examining the effectiveness of a hybrid cognitive behavioral therapy in the treatment of individuals with co-occurring anxiety disorders and alcohol dependence.

7 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog, Eli Lilly) using its proprietary technology BioChaperone).

7 Jan 2014

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

Tight blood pressure control urged in patients with cardiovascular disease

Intensive antihypertensive treatment to a systolic blood pressure target of 130 mmHg is equally beneficial for patients with and without established cardiovascular disease, research suggests.

6 Jan 2014

Scientists conduct clinical trial to determine silk clothing for treatment of eczema

Three hundred children are being recruited for a clinical trial to establish whether or not specialist silk clothing really does help in the treatment of eczema.

6 Jan 2014

BioLife Solutions announces preliminary revenue of $9 million for 2013

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.

6 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.

6 Jan 2014

New study highlights the importance of beta3-integrin protein in cancer research

A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).

6 Jan 2014

Gene-based technology for effective weight loss solutions

Losing weight is the most popular New Year's resolution for 2014, but research shows that only eight percent of people are successful in achieving their resolutions.

6 Jan 2014

RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

RegeneRx Biopharmaceuticals, Inc. announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development for its drug candidate, Thymosin beta 4 (Tβ4), for the treatment of Neurotrophic Keratopathy, a serious degenerative disease of the corneal epithelium (the outside layer of the eye).

5 Jan 2014

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

3 Jan 2014

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-Acute Coronary Syndrome patients.

2 Jan 2014

FDA removes partial clinical hold on Cell Therapeutics' Tosedostat aminopeptidase inhibitor

Cell Therapeutics, Inc. (CTI) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.

2 Jan 2014

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.

1 Jan 2014

Kessler Foundation to conduct pilot study on improving memory, function in MS patients

Kessler Foundation has been awarded a new grant by the National Multiple Sclerosis Society for a pilot study of memory and learning difficulties in individuals with MS. Scientists will test the effectiveness of using of self-generated learning in a treatment intervention to improve memory and functional performance.

1 Jan 2014

Clinical Trial News and Research

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Tight blood pressure control urged in patients with cardiovascular disease

Scientists conduct clinical trial to determine silk clothing for treatment of eczema

BioLife Solutions announces preliminary revenue of $9 million for 2013

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

New study highlights the importance of beta3-integrin protein in cancer research

Gene-based technology for effective weight loss solutions

RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

FDA removes partial clinical hold on Cell Therapeutics' Tosedostat aminopeptidase inhibitor

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Kessler Foundation to conduct pilot study on improving memory, function in MS patients

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery